Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €32.86 EUR
Change Today -0.08 / -0.24%
Volume 2.0
As of 8:17 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

roche holdings ltd-spons adr (RHO6) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - €34.25
52 Week Low
10/16/14 - €26.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

roche holdings ltd-spons adr (RHO6) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Europe, North America, and Asia. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. The company also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; pharmacogenomics; physical fitness and platelet function testing; PCR diagnostic systems; serum work area; urinalysis; and workflow solutions. In addition, it offers products for researchers, such as amplification, cell analysis, gene expression, gene knockdown, genome sequencing, microarrays, nucleic acid purification, protein analysis, PCR systems, and transfection products. The company has collaboration agreements with AmorChem, AbbVie, Xenon Pharmaceuticals, Stratos Genomics, The Garvan Institute, Cornell University, and University of Washington. The company was founded in 1896 and is headquartered in Basel, Switzerland.

88,509 Employees
Last Reported Date: 01/28/15
Founded in 1896

roche holdings ltd-spons adr (RHO6) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.3M
Chief Financial Officer and IT Officer
Total Annual Compensation: SFr.4.1M
Chief Operating Officer of Pharmaceuticals di...
Total Annual Compensation: SFr.5.0M
Chief Operating Officer of Diagnostics Divisi...
Total Annual Compensation: SFr.2.5M
General Counsel and Corporate Secretary
Total Annual Compensation: SFr.2.8M
Compensation as of Fiscal Year 2014.

roche holdings ltd-spons adr (RHO6) Key Developments

Roche to Invest EUR 570 Million in Bavarian Plant

Roche will invest more than EUR 570 million (USD 619.24 million) by end-March, 2017 in its site in the Bavarian city of Penzberg, in order to meet the increasing demand for biotech drugs and diagnostic tools. About EUR 330 million of the total will be spent on the expansion of pharma production and EUR 60 million on energy and services supply. A wastewater treatment system for EUR 26 million and a car park for EUR 4 million are currently under construction. At the end of July, 2015 the company will start expanding the diagnostics production which will cost about EUR 43 million. Further EUR 110 million will be invested in the construction of a new laboratory and an office complex. The expansion will lead to the creation of 170 new jobs.

Roche's Investigational Bladder-Cancer Treatment Leads to Shrinking of Tumours in Phase II Trial

Roche has announced that its programmed cell death-ligand 1(PD-L1) inhibitor, atezolizumab (MPDL3280A), was shown to be associated with shrinking of tumours in a Phase II study - IMvigor 210 - conducted in patients with locally advanced or metastatic urothelial bladder cancer (UBC) who had progressed on initial treatment, second-line or later. The company further noted that high levels of PD-L1 expression were shown to be correlated with increased responses to the candidate drug. IMvigor 210 is an open-label, multicentre, single-arm Phase II study assessing the safety and efficacy of atezolizumab in people with locally advanced or metastatic UBC, regardless of PD-L1 expression, with the primary endpoint of the study being overall response rate (ORR) and secondary endpoints being duration of response (DoR), overall survival (OS), progression-free survival (PFS) and safety. Apart from the IMvigor 210 study, Roche is also conducting a randomised Phase III study, IMvigor 211, comparing atezolizumab with standard-of-care chemotherapy in people who have relapsed UBC. In addition, a planned Phase III study, IMvigor 010, is set to assess atezolizumab compared with observation in people with early-stage muscle-invasive bladder cancer who are selected for PD-L1 expression and are at risk of recurrence (adjuvant). The Phase II results for the candidate immuno-oncology drug in UBC come after the company also presented Phase Ib trial data for atezolizumab in combination with a number of platinum-based chemotherapy combinations commonly used in the treatment of non-small-cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) this year.

Roche Announces Positive Results from Two Pivotal Studies Evaluating the Investigational Medicine ocrelizumab Compared with interferon beta-1a (Rebif)

Roche announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. The studies (called OPERA I and OPERA II) met their primary and major secondary endpoints. Treatment with ocrelizumab significantly reduced the annualised relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale (EDSS). Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain (areas of disease activity) compared with interferon beta-1a, as measured by MRI. Overall, the incidence of adverse events associated with ocrelizumab was similar to interferon beta-1a in both studies; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to interferon beta-1a. Further analyses of the OPERA studies are ongoing and detailed data will be presented at an upcoming medical congress. Results from a Phase III study of ocrelizumab in people with primary progressive MS (PPMS), a different form of MS, are expected later 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO6:GR €32.86 EUR -0.08

RHO6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $119.60 USD +1.74
Merck & Co Inc $59.05 USD +0.09
Novartis AG SFr.101.00 CHF -0.10
Pfizer Inc $36.15 USD +0.09
Sanofi €97.90 EUR -0.74
View Industry Companies

Industry Analysis


Industry Average

Valuation RHO6 Industry Range
Price/Earnings 26.0x
Price/Sales 4.6x
Price/Book 13.5x
Price/Cash Flow 21.2x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at